Related Articles by Review for PMID: 36943995

Year	Number of Results
2001	3
2002	2
2003	4
2004	1
2007	2
2008	1
2009	2
2010	2
2011	1
2012	1
2014	1
2015	2
2016	1
2018	2
2019	2
2020	2
2021	1
2022	1
2023	2
2024	2
2025	1

1

Relapsed and Refractory Follicular Lymphoma.

Singh D, Singh A, Mukkamalla SKR. Singh D, et al. 2023 Jan 15. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2023 Jan 15. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 36943995 Free Books & Documents.

2

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP. Plosker GL, et al. Drugs. 2003;63(8):803-43. doi: 10.2165/00003495-200363080-00005. Drugs. 2003. PMID: 12662126 Review.

3

An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.

Falchi L, Ferrajoli A, Jacobs I, Nava-Parada P. Falchi L, et al. Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):508-518.e14. doi: 10.1016/j.clml.2018.05.009. Epub 2018 May 23. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29934061 Free article. Review.

4

Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.

Keating GM. Keating GM. Drugs. 2010 Jul 30;70(11):1445-76. doi: 10.2165/11201110-000000000-00000. Drugs. 2010. PMID: 20614951 Review.

5

[Recent progress in the treatment of malignant lymphoma].

Ogura M. Ogura M. Gan To Kagaku Ryoho. 2001 Sep;28(9):1213-35. Gan To Kagaku Ryoho. 2001. PMID: 11579632 Review. Japanese.

6

Advancements in the Management of Follicular Lymphoma: A Comprehensive Review.

Merryman R, Mehtap Ö, LaCasce A. Merryman R, et al. Turk J Haematol. 2024 May 30;41(2):69-82. doi: 10.4274/tjh.galenos.2024.2024.0015. Epub 2024 Apr 25. Turk J Haematol. 2024. PMID: 38660754 Free PMC article. Review.

7

Revising the Treatment Pathways in Lymphoma: New Standards of Care-How Do We Choose?

Ngu H, Takiar R, Phillips T, Okosun J, Sehn LH. Ngu H, et al. Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-14. doi: 10.1200/EDBK_349307. Am Soc Clin Oncol Educ Book. 2022. PMID: 35594501 Free article. Review.

8

Rituximab therapy for indolent non-Hodgkin's lymphoma.

Hagenbeek A, Czuczman MS, Ghielmini M, Herold M, Kimby E, Solal-Céligny P, Unterhalt M. Hagenbeek A, et al. Anticancer Drugs. 2002 Nov;13 Suppl 2:S11-7. Anticancer Drugs. 2002. PMID: 12710586 Review.

9

First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma.

Hainsworth JD. Hainsworth JD. Semin Oncol. 2003 Feb;30(1 Suppl 2):9-15. doi: 10.1053/sonc.2003.50023. Semin Oncol. 2003. PMID: 12652459 Review.

10

A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.

Witzig TE, Nowakowski GS, Habermann TM, Goy A, Hernandez-Ilizaliturri FJ, Chiappella A, Vitolo U, Fowler N, Czuczman MS. Witzig TE, et al. Ann Oncol. 2015 Aug;26(8):1667-77. doi: 10.1093/annonc/mdv102. Epub 2015 Feb 23. Ann Oncol. 2015. PMID: 25712458 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

33 results

Results by year

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Related Articles by Review for PMID: 36943995

33 results

Results by year